
|Videos|December 27, 2018
Overview of R2 Regimen for Relapsed Follicular Lymphoma
Author(s)Andre Goy, MD
Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R<sup>2</sup> regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br />
Advertisement
Andre Goy, MD, chief, division of lymphoma, chairman and director, John Theurer Cancer Center, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide (Revlimid) plus rituximab (Rituxan), also known as the R2regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.
In this patient population, rituximab monotherapy was standard treatment, but this was not an appealing option for older patients. The data support R2
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
KLN-1010 In Vivo CAR Achieves 100% MRD Negativity in R/R Myeloma
2
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
3
FDA Grants Priority Review to Adjuvant Atezolizumab for dMMR Colon Cancer
4
ASCO 2026 Breast Cancer Highlights: Beyond the LBAs
5







































